Cravatt Benjamin bought ALNY
June 1, 2026 · Form 4 insider transaction
Cravatt Benjamin bought 4,393 shares of Alnylam Pharmaceuticals, Inc. at $0.00 per share, a transaction worth N/A. The trade was recorded as grant or award and disclosed on an SEC Form 4, filed 2 days after the transaction.
Direction
Acquired (buy-side)
Shares
4,393
Price
$0.00
Total value
N/A
InsiderCravatt Benjamin
RoleDirector
SecurityStock Option (Right to Buy)
Transaction codeA: Grant or award
Transaction dateJune 1, 2026
Filing dateJune 3, 2026
Shares owned after4,393
OwnershipDirect
10b5-1 planNo
AmendedNo
Footnotes
The stock option will vest as to one third of the shares on each of the first, second and third anniversaries of the date of grant.